Actively enrolling clinical trials
| NCT No. . | Title . | Drug . | Enrollment . | Randomization . | Study phase . |
|---|---|---|---|---|---|
| NCT03593915 | A Phase 1b/2 Study of Alvocidib Plus Decitabine in Patients With MDS | Decitabine | 49 | None | 1| 2 |
| NCT03045510 | Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent | Decitabine | 50 | None | 2 |
| NCT02781883 | Clinical Trial of BP1001(Liposomal Grb2 Antisense Oligonucleotide) in Combination With Decitabine in AML / High Risk MDS | Decitabine | 108 | None | 2 |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS | Decitabine | 3 | None | 1 |
| NCT02269280 | Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) | Decitabine/Azacitidine | 240 | Yes | 2 |
| NCT03066648 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | Decitabine/Azacitidine | 235 | None | 1 |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | Decitabine | 65 | None | 1|2 |
| NCT01515527 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Decitabine | 160 | None | 2 |
| NCT03502668 | Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS | Decitabine | 160 | Yes | 1|2 |
| NCT02890329 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Decitabine | 48 | None | 1 |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Decitabine | 18 | None | 1 |
| NCT03946670 | A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | Decitabine/Azacitidine | 120 | Yes | 2 |
| NCT03404193 | Venetoclax in Combination With Decitabine in r/r AML and MDS | Decitabine | 280 | None | 2 |
| NCT03661307 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Decitabine/Azacitidine | 52 | None | 1|2 |
| NCT03356080 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | Decitabine | 50 | None | 2 |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Decitabine | 80 | None | 1|2 |
| NCT03906695 | Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes | Decitabine | 30 | None | 1 |
| NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | Azacitidine | 156 | Yes | 3 |
| NCT02942290 | A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) | Azacitidine | 80 | None | 1 |
| NCT02985190 | A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders | Azacitidine | 30 | None | 2 |
| NCT03978364 | A Study of Azacitidine with or without homoharringtonine for Patients With Int/High -Risk MDS and AML-MRC | Azacitidine | 100 | Yes | 3 |
| NCT03113643 | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Azacitidine | 56 | None | 1 |
| NCT02530463 | Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Azacitidine | 120 | None | 2 |
| NCT03564873 | Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS | Azacitidine | 51 | None | 1|2 |
| NCT03094637 | Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome | Azacitidine | 40 | None | 2 |
| NCT03338348 | Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | Azacitidine | 168 | None | 2 |
| NCT02750995 | Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML | Azacitidine | 15 | None | 1 |
| NCT03217903 | High Risk Myelodysplasia Treated by Azacytidine: Genetic and Epigenetic (MYRAGE) | Azacitidine | 32 | None | Not applicable |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | Azacitidine | 500 | Yes | 1|2 |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Azacitidine | 156 | None | 1 |
| NCT03268954 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | Azacitidine | 450 | Yes | 3 |
| NCT02807558 | A Biomarker-Directed phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Azacitidine | 162 | None | 2 |
| NCT03397173 | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | Azacitidine | 28 | None | 2 |
| NCT02553941 | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | Azacitidine | 24 | None | 1 |
| NCT04022785 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Azacitidine | 32 | None | 1 |
| NCT03814005 | A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment | Azacitidine | 60 | None | 1 |
| NCT03047993 | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Azacitidine | 40 | None | 1|2 |
| NCT03248479 | Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies | Azacitidine | 96 | None | 1 |
| NCT03383575 | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Azacitidine | 105 | None | 2 |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation (Azacitidine and Vitamin C) in MDS, CMML, AML | Azacitidine | 182 | Yes | 2 |
| NCT03873311 | Azacytidine + HAG Regimen in Elderly Patients With Myeloid Malignancy. | Azacitidine | 120 | None | 3 |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant | Decitabine/Azacitidine | 60 | Yes | 2 |
| NCT01787487 | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Azacitidine | 125 | None | 2 |
| NCT02981615 | Phase 3 Multicenter Randomized Double-blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients | Azacitidine | 170 | Yes | 3 |
| NCT03493646 | Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | Azacitidine | 60 | None | 2 |
| NCT03326310 | Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia | Azacitidine | 18 | None | 1 |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Azacitidine | 18 | None | 1 |
| NCT03471260 | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies | Azacitidine | 48 | None | 1|2 |
| NCT02038777 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | Azacitidine | 49 | None | 1 |
| NCT No. . | Title . | Drug . | Enrollment . | Randomization . | Study phase . |
|---|---|---|---|---|---|
| NCT03593915 | A Phase 1b/2 Study of Alvocidib Plus Decitabine in Patients With MDS | Decitabine | 49 | None | 1| 2 |
| NCT03045510 | Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent | Decitabine | 50 | None | 2 |
| NCT02781883 | Clinical Trial of BP1001(Liposomal Grb2 Antisense Oligonucleotide) in Combination With Decitabine in AML / High Risk MDS | Decitabine | 108 | None | 2 |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS | Decitabine | 3 | None | 1 |
| NCT02269280 | Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS) | Decitabine/Azacitidine | 240 | Yes | 2 |
| NCT03066648 | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | Decitabine/Azacitidine | 235 | None | 1 |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | Decitabine | 65 | None | 1|2 |
| NCT01515527 | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Decitabine | 160 | None | 2 |
| NCT03502668 | Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS | Decitabine | 160 | Yes | 1|2 |
| NCT02890329 | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Decitabine | 48 | None | 1 |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Decitabine | 18 | None | 1 |
| NCT03946670 | A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | Decitabine/Azacitidine | 120 | Yes | 2 |
| NCT03404193 | Venetoclax in Combination With Decitabine in r/r AML and MDS | Decitabine | 280 | None | 2 |
| NCT03661307 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Decitabine/Azacitidine | 52 | None | 1|2 |
| NCT03356080 | DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess | Decitabine | 50 | None | 2 |
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Decitabine | 80 | None | 1|2 |
| NCT03906695 | Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes | Decitabine | 30 | None | 1 |
| NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | Azacitidine | 156 | Yes | 3 |
| NCT02942290 | A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) | Azacitidine | 80 | None | 1 |
| NCT02985190 | A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders | Azacitidine | 30 | None | 2 |
| NCT03978364 | A Study of Azacitidine with or without homoharringtonine for Patients With Int/High -Risk MDS and AML-MRC | Azacitidine | 100 | Yes | 3 |
| NCT03113643 | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Azacitidine | 56 | None | 1 |
| NCT02530463 | Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) | Azacitidine | 120 | None | 2 |
| NCT03564873 | Omacetaxine + Azacitidine in Untreated Patients With High Grade MDS | Azacitidine | 51 | None | 1|2 |
| NCT03094637 | Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome | Azacitidine | 40 | None | 2 |
| NCT03338348 | Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | Azacitidine | 168 | None | 2 |
| NCT02750995 | Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML | Azacitidine | 15 | None | 1 |
| NCT03217903 | High Risk Myelodysplasia Treated by Azacytidine: Genetic and Epigenetic (MYRAGE) | Azacitidine | 32 | None | Not applicable |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | Azacitidine | 500 | Yes | 1|2 |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Azacitidine | 156 | None | 1 |
| NCT03268954 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | Azacitidine | 450 | Yes | 3 |
| NCT02807558 | A Biomarker-Directed phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Azacitidine | 162 | None | 2 |
| NCT03397173 | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | Azacitidine | 28 | None | 2 |
| NCT02553941 | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | Azacitidine | 24 | None | 1 |
| NCT04022785 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Azacitidine | 32 | None | 1 |
| NCT03814005 | A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment | Azacitidine | 60 | None | 1 |
| NCT03047993 | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Azacitidine | 40 | None | 1|2 |
| NCT03248479 | Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies | Azacitidine | 96 | None | 1 |
| NCT03383575 | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Azacitidine | 105 | None | 2 |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation (Azacitidine and Vitamin C) in MDS, CMML, AML | Azacitidine | 182 | Yes | 2 |
| NCT03873311 | Azacytidine + HAG Regimen in Elderly Patients With Myeloid Malignancy. | Azacitidine | 120 | None | 3 |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant | Decitabine/Azacitidine | 60 | Yes | 2 |
| NCT01787487 | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Azacitidine | 125 | None | 2 |
| NCT02981615 | Phase 3 Multicenter Randomized Double-blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients | Azacitidine | 170 | Yes | 3 |
| NCT03493646 | Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | Azacitidine | 60 | None | 2 |
| NCT03326310 | Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia | Azacitidine | 18 | None | 1 |
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Azacitidine | 18 | None | 1 |
| NCT03471260 | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies | Azacitidine | 48 | None | 1|2 |
| NCT02038777 | A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies | Azacitidine | 49 | None | 1 |